@article{article_1539734, title={Determination of Etiology and Risk Factors in Patients Applying to Our Outpatient Clinic for Weight Loss}, journal={Cumhuriyet Medical Journal}, volume={46}, pages={198–204}, year={2024}, DOI={10.7197/cmj.1539734}, author={Mühürdaroğlu, Ayşe Münevver and Akdağ, İbrahim and Taştemur, Mercan}, keywords={Obesity, body mass index, vitamin D, HOMA-IR, hip circumference, fasting plasma glucose, LDL, insulin, waist / hip circumference}, abstract={Archive information of 100 patients who applied to Ankara University Health Sciences University Dışkapı Yıldırım Beyazıt Training and Research Hospital Internal Diseases Polyclinic between 01 December 2016 and 01 June 2017 with a desire to lose weight was examined. Patients who were excluded from exclusion criteria and whose BMI was m2 25 kg / m2 were included in the study. Age, gender, curriculum vitae, blood pressure, anthropometric measurements and laboratory data recorded in patient files were used in the routine functioning of the Internal Diseases Polyclinic. Measurements and blood tests were done in the morning hours after at least 8 hours of fasting. The data of the study were analyzed using Statistical Package for the Social Sciences (SPSS) statistical package program. Size E: 178.00 (165-186), K: 161.00 (150-185) (p <0.001) and body weight E: 100.00 (76-134), K: 87.00 (66-140 ) (p <0.001). Waist / hip circumference ratio was E: 0.88 ± 0.09, K: 0.83 ± 0.06 (p = 0.02). TPG K: 94.00 (61-218), E: 101.00 (70-219) (p = 0.05). HDL E: 41.00 (28-141), K: 48.00 (31-78) (p = <0.01). Vitamin B12 K: 215.00 (97-1500), E: 188.00 (107-394) (p: 0.04). HOMA IR Overweight: 1.57 (0. 5-5.7), Stage 1 Obese: 2.19 (0.55-20.20), Stage 2 Obese: 2.80 (1.09- 12. 7), Stage 3 Obese: 3.06 (0.42-6.2 ) (p: 0.002). Waist circumference; overweight: 89.86 ± 10.71, Stage 1: 95.30 ± 16.51, Stage 2: 104.52 ± 9.04, Stage 3 obese: 114.88 ± 11.75 (p <0.001). Hip circumference; overweight: 107.0 (97-125), Stage 1: 114.0 (96-134), Stage 2: 125.0 (101-140), Stage 3: 130.0 (111-150) ( <p : 0.001). Body weight; overweight: 78.0 (66-100), Stage 1: 88.0 (75-159), Stage 2: 88.0 (75-159), Stage 3: 94.0 (83-134), Stage 4 : 116.0 (94-140) (p <0.01). LDL overweight: 114.17 ± 29.82, Stage 1: 130.58 ± 34.80, Stage 2: 137.34 ± 29.31, Stage 3: 119.22 ± 22.98 (p: 0.04 ). Insulin overweight: 7.8 (0.57-25.4), Stage 1: 9.90 (3.1-82.1), Stage 2: 13.07 (4.11-53.2), Stage 3: 11.2 (2.24-29.3) (p: 0.00). APG; overweight: 86.0 (61-133), Stage 1: 90.00 (72-155), Stage 2: 92.00 (71-136), Stage 3: 97.00 (76-115) (p: 0,04) As a result of our study, as the BMI increases in accordance with the literature, APG, HOMA-IR, insulin, hip circumference, waist / hip ratio, LDL, platelet count, folate levels increase. We also found that vitamin D levels decreased as BMI increased. We have seen that the highest awareness rate is in the overweight group. In addition to these results, we encountered new questions that should be answered such as the dose and necessity of vitamin D replacement in obese patients, and preventing unnecessary tests such as anti tpo and anti tg. We have seen that new studies are needed in different areas on a larger scale.}, number={3}, publisher={Sivas Cumhuriyet University}